Picton Mahoney Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Picton Mahoney Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$11M	–	1270
2025 Q4	$11M	Buy	+50,000	New	+$8.08M	0.09%	190

Picton Mahoney Asset Management's CDTX Position: Q1 2026 in Review

Picton Mahoney Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 75,000 shares — an estimated $16.6M sold.

Picton Mahoney Asset Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $16.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Picton Mahoney Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Picton Mahoney Asset Management sold 75,000 Cidara Therapeutics shares in Q1 2026, an estimated $16.6M.
Picton Mahoney Asset Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Picton Mahoney Asset Management's Cidara Therapeutics position peaked at $16.6M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.